Member Info for saigonsally

"Never ever ever ever ever look at tin content, only look at the cassiterite content because cassiterite is the only economically valuable mineral of tin..."

As soon as I saw the $10m milestone payment I knew we'd be marked down. Ain't no pleasing some people... Absurdly low valuation

Absolutely unbelieveable - except that nothing is unbelieveable with this stock...

HUTCHMED recently presented (Dec. 2024) additional, highly encouraging, long-term clinical data for sovleplenib in the treatment of immune thrombocytopenia (ITP) at the 2024 American Society of Haematology (ASH) annual meeting, which we believe is likely to have further elevated the drug’s profile amongst both the clinical and industrial community. The launch of sovleplenib in China is anticipated in 2025, with the China market alone representing a cUS$500-700m market opportunity, according to HCM.

IF - outstanding. A dozen upticks...

Wow, the Chairman really putting his money where his mouth is. What a bold statement of faith in your company Mr Chairman. How abourt resigning and letting some actual businessmen run this show?

1Pencil, I've just received the Cavendish note, 16 pages of which I reproduce the first para...

H1 2024 interims US Fruzaqla momentum continues HUTCHMEDs H1 2024 interim results require investors to look beyond the headline group revenue figures to the growth of the companys underlying drug product portfolio which was buoyed by the strong commercial uptake of Fruzaqla in the US market. Total in-market sales of HUTCHMEDs products grew 140% (145% CER) YoY to $243m, translating into a rise of consolidated revenues to HUTCHMED of 59% (64% CER) YoY to $128m. This growth was catalysed by the uptake of Fruzaqla, which generated H1 2024 sales of $131m, a figure which has now surpassed consensus' 2024 full-year expectations of c.$125m. With Fruzaqla posting Q1/Q2 growth of 40%, we believe the drug is now well on its way to achieving global sales of at least $200m in 2024. Additionally, the strength of HUTCHMEDs balance sheet, which boasted gross cash, cash equivalents and short-term investments of $802m at endJune 2024, continues to provide a significant competitive advantage over peers, in our view, given the still tight biopharma funding environment.

PANMURE LIBERUM: HUTCHMED: The building blocks of sustainability.

Sorry folks that's as far as I got on my free account but there's 26 pages more where that came from...

I look forward to that. Unfortunately today only a glowing piece about Wegovy and Ozempic.

"Gearing up for the Chinese market with sovleplenib HUTCHMED’s R&D day is likely to have further fuelled investor confidence in the substantial value to be captured if approval by China’s regulators is received for the company’s first immunology asset, sovleplenib, for the treatment of the rare bleeding condition immune thrombocytopenia (ITP). Following the success of the phase III ESLIM-01 study and the strength of the clinical data (safety and efficacy) acquired for sovleplenib, we are confident that approval in China should now be a formality and we expect to hear a decision by the regulators by the end of 2024 or early 2025 with a full launch next year. An approval would open up the highly lucrative ITP market in China, which is currently valued at about US$500-700m, and with sovleplenib being a differentiating first in-class treatment for ITP, we believe there is significant commercial value to be realised. We currently model sovleplenib sales in China to exceed US$200m by 2029, which we believe should be considered conservative."

data at eha 2024 heighten focus on sovleplenib hutchmed’s clinical data presentations at the european hematology association (eha) 2024 congress have provided meaningful insights into sovleplenib’s efficacy and safety profile. this is the first hutchmed immunology/haem-oncology asset to be filed in china, with a potential approval decision in ≥2l immune thrombocytopenia (itp) expected late-2024. the prospect of china approvals for sovleplenib and followon indications for fru*****inib, as well as the first potential fru*****inib regulatory decision for advanced metastatic colorectal cancer (mcrc) in japan (following its recent european approval) could round off a busy 2024. continued commercial execution underpins the fy24 expectation for oncology/immunology consolidated revenues of $300-$400m, driven by targeted 30-50% growth in marketed product sales and royalties. our hutchmed valuation is increased c 5% to $6.10bn/£5.09bn/hk$47.61bn, or $35.03/ads and 584p/hk$54.64 per share.

from cavendish

hutchmed has announced that its global (ex-china) strategic partner takeda has received notification from the european commission on the approval of fruzaqla (fru*****inib) as a fourth line treatment for metastatic colorectal cancer (mcrc). the approval marks a major milestone in the global rollout of fruzaqla with europe representing one of the most significant commercial markets outside of the us. the successful launch experienced by fruzaqla in the us, following its approval in november 2023, provides strong clinical and commercial validation which we believe bodes well for the uptake of the drug in europe. in our view, fruzaqla is capable of achieving global sales of at least us$200m in 2024 and that the market is being too conservative in its forecasts with evaluatepharma consensus’ currently estimating 2024 sales of fruzaqla of cus$90m. - strong us launch. the ex-china rollout for fruzaqla began in november 2023 with takeda leading the global commercialisation efforts for the drug. since the us launch, fruzaqla has experienced a strong uptake amongst clinicians generating us sales of c$15m in 2023 and q1 2024 sales of c$55m. the eu approval opens another major market that further expands the commercial footprint for fruzaqla and the success of the us launch bodes well for the drug’s traction in europe, in our view.

TDT, I have to agree with you 100%. And at this rate by the time ATM have lithium to sell the world will have switched from lithium to sodium.

It's paid-for research but a few highlights:

Investment thesis

HUTCHMED is a China based, sales generating, biopharmaceutical company focussed on the

development of innovative medicines for the treatment of cancer and immunological diseases. To

date, HUTCHMED has launched three, internally developed, oncology drugs in China (Elunate,

Orpathys and Sulanda) and one drug in the US (Fruzaqla), which it has executed through both

internal-commercialisation and strategic partnerships. The approval of Fruzaqla in the US in

November 2023 marked a significant milestone for HUTCHMED and the strategic expansion of its

portfolio into the highly lucrative US market.

The key value drivers that form the foundation of our underlying investment thesis for HUTCHMED

are:

- HUTCHMED is a revenue growing biopharmaceutical company, with its pharmaceutical

products experiencing strong commercial traction in both China and the US.

- HUTCHMED is expected to become a self-sustaining, profitable business by 2025.

- HUTCHMED has established strategic partnerships with some of the world’s largest

pharmaceutical companies with global partnerships for Fruzaqla and Orpathys with Takeda and

AstraZeneca, respectively and a China partnership with Eli Lilly for Elunate.

- HUTCHMED has a significant pipeline of 14 drug candidates involved in c40 active clinical

studies, 16 of which are in Phase III registrational or Phase II registration-intent studies,

providing multiple shots on goal and helping derisk the company’s equity thesis.

In our view, there are two fundamental components of the HUTCHMED investment thesis that the

market has not yet priced in:

(i) The growth of Fruzaqla in the US

(ii) The value of sovleplenib

- Sovleplenib has already successfully completed a Chinese phase III trial and we believe the

presentation of more detailed clinical data from the study at the European Haematology

Association conference in June 2024 could result in a significant rerating of the stock.

- If approved, we estimate sovleplenib annual sales in China alone could exceed US$100m by

2027 and US$200m by 2029. Our forecasts do not currently account for sovleplenib sales-ex China which could unlock

significant future value and upside should a clinical strategy involving expansion into the US

market or licensing deal materialise.

Brilliant, indeed I can, many thanks 1pencil. Now to understand what they are saying ;)

As of now Halifax have neither paid my NG dividend nor have they added the new shares to my account, they are still untradable. They are slovenly in the extreme happily earning interest on my and other shareholders' money...

Jatw, annoyingly the press release does not give any valuation and I don't want to upgrade my subscription to Research Tree to read the doc, sorry...!

Nice to see Cavendish initiating coverage with a 77 page report.

"HUTCHMED - Building a credible, validated, and global oncology franchise"

Excellent interview. I fail to understand the measly market valuation placed on this company

Yes, Halifax have taken my funds too and I was allocated double my official allowance but not quite all that I bid for. The New Ordinary shares are quoted at 217.45 as opposed to the Ordinaries at 868. Will the new shares increase in value on 12 June to match the Ordinaries...? I hope so...!